Bharat Biotech Initiates P-III Study for Covaxin Against COVID-19

 Bharat Biotech Initiates P-III Study for Covaxin Against COVID-19

Bharat Biotech Initiates P-III Study for Covaxin Against COVID-19

Shots:

  • Following the successful completion of the interim analysis from the P-I & P-II clinical trials of Covaxin, the company has received the DCGI approval to conduct a P-III study of its COVID-19 vaccine
  • The study will assess Covaxin (6mcg, IM at an interval of 28days) vs PBO in ~26,000 volunteers in a ratio (1:1) aged ≥18yrs. in over 25 centers across India and is being conducted in partnership with ICMR. It is the largest clinical trial conducted for a COVID-19 vaccine in India
  • Bharat Biotech plans to launch Covaxin by June’2021, unless the government decides to give the vaccine a EUA before that, based on data from earlier phases of clinical trial

Source 1, Source 2 ­to­ read full press release/ article | Ref: Bharat Biotech, NDTV | Image: MediCircle

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post